Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 331-335

  Wu, Yao Kuang ^a   Chen, Kuei Tien ^b   Kuo, Yung Bin ^b,c   Huang, Ya Shu ^b   Chan, Err Cheng ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Lung cancer; Pleural effusion; Prognosis; Survival rate; Survivin expression

Indexed keywords

SURVIVIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL EFFUSION, MALIGNANT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 57449085352     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.023     Document Type: Article

References (30)

1. Fiegl M., Massoner A., Steurer M., et al. Improving tumor cell detection in pleural effusions by interphase cytogenetics. Cytometry B Clin. Cytom. 55 (2003) 60-62
2. Fenton K.N., and Richardson J.D. Diagnosis and management of malignant pleural effusions. Am. J. Surg. 170 (1995) 69-74
3. Yang P.C., Luh K.T., Kuo S.H., et al. Immunocytochemistry and ELISA quantitation of mucin for diagnosis of malignant pleural effusions. Am. Rev. Respir. Dis. 146 (1992) 1571-1575
4. Yang C.T., Lee M.H., Lan R.S., et al. Telomerase activity in pleural effusions: diagnostic significance. J. Clin. Oncol. 16 (1998) 567-573
5. Duffy M.J. Clinical uses of tumor markers: a critical review. Crit. Rev. Clin. Lab. Sci. 38 (2001) 225-262
6. Deveraux Q.L., and Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
7. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 (2003) 46-54
8. Li F. Survivin study: what is the next wave?. J. Cell. Physiol. 197 (2003) 8-29
9. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4 (2004) 592-603
10. Yang D., Welm A., and Bishop J.M. Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. USA 101 (2004) 15100-15105
11. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
12. Velculescu V.E., Madden S.L., Zhang L., et al. Analysis of human transcriptomes. Nat. Genet. 23 (1999) 387-388
13. Monzo M., Rosell R., Felip E., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17 (1999) 2100-2104
14. Rosell R., Li S., Skacel Z., et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8 (1993) 2407-2412
15. de Anta J.M., Jassem E., Rosell R., et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 15 (1997) 2951-2958
16. Schultz I.J., Witjes J.A., Swinkels D.W., et al. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin. Chim. Acta 368 (2006) 20-32
17. Smith S.D., Wheeler M.A., Plescia J., et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
18. Shariat S.F., Casella R., Khoddami S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 171 (2004) 626-630
19. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
20. Weikert S., Christoph F., Schrader M., et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int. J. Cancer 116 (2005) 100-104
21. Leibowitz S., Kennedy L., and Lessof M.H. The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum. Br. J. Exp. Pathol. 54 (1973) 152-162
22. Ellner J.J., Barnes P.F., Wallis R.S., et al. The immunology of tuberculous pleurisy. Semin. Respir. Infect. 3 (1988) 335-342
23. Shinozawa I., Inokuchi K., Wakabayashi I., et al. Disturbed expression of the anti-apoptosis gene, survivin and EPR-1 in hematological malignancies. Leuk. Res. 24 (2000) 965-970
24. Verneris M.R., Kornacker M., Mailander V., et al. Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis. Cancer Immunol. Immunother. 49 (2000) 335-345
25. Sharief M.K., and Semra Y.K. Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 119 (2001) 358-364
26. Adida C., Berrebi D., Peuchmaur M., et al. Anti-apoptosis gene, survivin and prognosis of neuroblastoma. Lancet 351 (1998) 882-883
27. Adida C., Haioun C., Gaulard P., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
28. Sarela A.I., Macadam R.C., Farmery S.M., et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
29. Span P.N., Sweep F.C., Wiegerinck E.T., et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin. Chem. 50 (2004) 1986-1993
30. Ryan B.M., Konecny G.E., Kahlert S., et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol. 17 (2006) 597-604